Role of gp91phox-containing NADPH oxidase in left ventricular remodeling induced by intermittent hypoxic stress

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 5, 2008, Pages

  Hayashi, Tetsuya ^a   Yamashita, Chika ^a   Matsumoto, Chika ^a   Kwak, Chol Jun ^a   Fujii, Kiwako ^a   Hirata, Tomoko ^a   Miyamura, Masatoshi ^a   Mori, Tatsuhiko ^a   Ukimura, Akira ^a   Okada, Yoshikatsu ^a   Matsumura, Yasuo ^a   Kitaura, Yasushi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Cardiac hypertrophy; Oxidative stress; Sleep apnea; Superoxide

Indexed keywords

4 HYDROXYNONENAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; 4-HYDROXY-2-NONENAL; ALDEHYDE; CYBB PROTEIN, MOUSE; INTERLEUKIN 6; LIPID PEROXIDE; MEMBRANE PROTEIN; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; GEL MOBILITY SHIFT ASSAY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; HEMODYNAMICS; HISTOLOGY; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLEEP APNEA SYNDROME; ANIMAL; ANOXIA; BLOOD; BLOOD PRESSURE; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE PRESSURE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY;

ALDEHYDES; ANIMALS; ANOXIA; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; INTERLEUKIN-6; LIPID PEROXIDES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NADPH OXIDASE; NF-KAPPA B; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUPEROXIDES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 44949261055     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.91496.2007     Document Type: Article

References (37)

1. Alchanatis M, Tourkohoriti G, Kosmas EN, Panoutsopoulos G, Kakouros S, Papadima K, Gaga M, Jordanoglou JB. Evidence for left ventricular dysfunction in patients with obstructive sleep apnoea syndrome. Eur Respir J 20: 1239-1245, 2002.
2. Babior BM. NADPH oxidase: an update. Blood 93: 1464-1476, 1999.
3. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996.
4. phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105: 293-296, 2002.
5. Border WA, Nobel NA. Transforming growth factor-β in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
6. Campen MJ, Shimoda LA, O'Donnell CP. Acute and chronic cardiovascular effects of intermittent hypoxia in C57BL/6J mice. J Appl Physiol 99: 2028-2035, 2005.
7. Chen L, Einbinder E, Zhang Q, Hasday J, Balke CW, Scharf SM. Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Respir Crit Care Med 172: 915-920, 2005.
8. Eghbali M, Tomek R, Sukhatme VP, Woods C, Bhambi B. Differential effects of transforming growth factor-β1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 69: 483-490, 1991.
9. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 109: S81-S96, 2002.
10. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 87: 26-32, 2000.
11. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
12. Hayashi T, Ijiri Y, Toko H, Shimomura H, Okabe M, Terasaki F, Kitaura Y, Kawamura K. Increased digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy. Eur Heart J 21: 296-305, 2000.
13. Hayashi T, James TN, Buckingham DC. Ultrastructure and immunohistochemistry of the coronary chemoreceptor in human and canine hearts. Am Heart J 129: 946-959, 1995.
14. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41: 2164-2171, 2003.
15. Inamoto S, Hayashi T, Tazawa N, Mori T, Yamashita C, Nakano D, Matsumura Y, Okuda N, Sohmiya K, Sakai A, Furuya E, Kitaura Y. Angiotensin II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. Circ J 70: 787-792, 2006.
16. Joyeux-Faure M, Stanke-Labesque F, Lefebvre B, Béguin P, Godin-Ribuot D, Ribuot C, Launois SH, Bessard G, Lévy P. Chronic intermittent hypoxia increases infarction in the isolated rat heart. J Appl Physiol 98: 1691-1696, 2005.
17. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, Utsumi H, Takeshita A. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 87: 392-398, 2000.
18. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 41: 1429-1437, 2003.
19. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40: 477-484, 2002.
20. Li Y, Ha T, Gao X, Kelley J, Williams DL, Browder IW, Kao RL, Li C. NF-κB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 287: H1712-H1720, 2004.
21. phox). Am J Physiol Lung Cell Mol Physiol 290: L2-L10, 2006.
22. Liu SF, Malik AB. NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290: L622-L645, 2006.
23. Liu SF, Ye X, Malik AB. Inhibition of NF-κB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 100: 1330-1337, 1999.
24. Minoguchi K, Tazaki T, Yokoe T, Minoguchi H, Watanabe Y, Yamamoto M, Adachi M. Elevated production of tumor necrosis factor-α by monocytes in patients with obstructive sleep apnea syndrome. Chest 126: 1473-1479, 2004.
25. 2 modulate superoxide anion production in bovine cardiac myocytes: potential role of NADH oxidase. Circulation 96: 614-620, 1997.
26. Mori T, Chen YF, Feng JA, Hayashi T, Oparil S, Perry G. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res 61: 771-779, 2004.
27. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 71: 208-215, 2006.
28. Nakashima H, Katayama T, Takagi C, Amenomori K, Ishizaki M, Honda Y, Suzuki S. Obstructive sleep apnoea inhibits the recovery of left ventricular function in patients with acute myocardial infarction. Eur Heart J 27: 2317-2322, 2006.
29. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996.
30. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schlüter KD, Böhm M. Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1. Am J Physiol Heart Circ Physiol 283: H1253-H1262, 2002.
31. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci USA 103: 7432-7437, 2006.
32. Siwik DA, Tzortzis JD, Pimental DR, Chang DL, Pagano PJ, Singh K, Sawyer DB, Colucci WS. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 85: 147-153, 1999.
33. Sodhi CP, Kanwar YS, Sahai A. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 284: H846-H852, 2003.
34. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 88: 947-953, 2001.
35. Yamashita C, Hayashi T, Mori T, Tazawa N, Kwak C, Nakano D, Sohmiya K, Okada Y, Kitaura Y, Matsumura Y. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 30: 1219-1230, 2007.
36. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107: 1129-1134, 2003.
37. Zakheim RM, Molteni A, Mattioli L, Park M. Plasma angiotensin II levels in hypoxic and hypovolemic stress in unanesthetized rabbits. J Appl Physiol 41: 462-465, 1976.